Elena Guerini

1.0k total citations
29 papers, 793 citations indexed

About

Elena Guerini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Elena Guerini has authored 29 papers receiving a total of 793 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Elena Guerini's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Elena Guerini is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Elena Guerini collaborates with scholars based in Switzerland, United States and United Kingdom. Elena Guerini's co-authors include Norberto Perico, Lidia Mosconi, Giuseppe Remuzzi, Flavio Gaspari, Piero Ruggenenti, Carmen S. Amuchastegui, Erica Daina, Peter N. Morcos, Alex Phipps and Neil Parrott and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American Society of Nephrology.

In The Last Decade

Elena Guerini

29 papers receiving 771 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elena Guerini Switzerland	15	227	222	208	191	81	29	793
Jie Ling United States	11	288 1.3×	276 1.2×	255 1.2×	195 1.0×	46 0.6×	18	981
Michael Gillen United States	17	239 1.1×	170 0.8×	85 0.4×	80 0.4×	110 1.4×	55	693
Song Ren China	13	105 0.5×	69 0.3×	256 1.2×	155 0.8×	130 1.6×	33	953
Sameh R. Abul‐Ezz United States	14	122 0.5×	111 0.5×	179 0.9×	133 0.7×	147 1.8×	26	800
Chantal Le Guellec France	21	89 0.4×	126 0.6×	286 1.4×	213 1.1×	134 1.7×	59	1.3k
Daniel J. Crona United States	17	54 0.2×	494 2.2×	248 1.2×	350 1.8×	52 0.6×	51	1.2k
Lisa J. Benincosa United States	14	61 0.3×	71 0.3×	83 0.4×	248 1.3×	92 1.1×	29	804
Huang Sm United States	12	52 0.2×	94 0.4×	329 1.6×	208 1.1×	359 4.4×	26	1.1k
Marshall P. Goren United States	18	63 0.3×	175 0.8×	198 1.0×	203 1.1×	21 0.3×	35	797
Sachin R. Jhawar United States	14	107 0.5×	109 0.5×	245 1.2×	184 1.0×	15 0.2×	84	755

Countries citing papers authored by Elena Guerini

Since Specialization

Citations

This map shows the geographic impact of Elena Guerini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Guerini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Guerini more than expected).

Fields of papers citing papers by Elena Guerini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Guerini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Guerini. The network helps show where Elena Guerini may publish in the future.

Co-authorship network of co-authors of Elena Guerini

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Guerini. A scholar is included among the top collaborators of Elena Guerini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Guerini. Elena Guerini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jamois, Candice, David C. Turner, Leonid Gibiansky, et al.. (2025). Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL. Clinical Pharmacology & Therapeutics. 118(4). 917–927. 1 indexed citations

Djebli, Nassim, et al.. (2023). Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager glofitamab. CPT Pharmacometrics & Systems Pharmacology. 13(3). 396–409. 7 indexed citations

Meneses‐Lorente, Georgina, Elena Guerini, François Mercier, et al.. (2023). Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations. Cancer Chemotherapy and Pharmacology. 91(3). 239–246. 2 indexed citations

Dziadziuszko, Rafał, Solange Peters, Thorsten Ruf, et al.. (2022). Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib. ESMO Open. 7(6). 100612–100612. 14 indexed citations

Djebli, Nassim, Neil Parrott, Elena Guerini, et al.. (2021). Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making. European Journal of Drug Metabolism and Pharmacokinetics. 46(6). 779–791. 10 indexed citations

Meneses‐Lorente, Georgina, Stephen Fowler, Elena Guerini, et al.. (2021). In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). Investigational New Drugs. 40(1). 68–80. 12 indexed citations

Hsu, Joy, Elena Guerini, Bogdana Balas, et al.. (2021). Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer. CPT Pharmacometrics & Systems Pharmacology. 10(11). 1357–1370. 8 indexed citations

Meneses‐Lorente, Georgina, Darren Bentley, Elena Guerini, et al.. (2021). Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors. Investigational New Drugs. 39(3). 803–811. 26 indexed citations

Parrott, Neil, Cordula Stillhart, Marc Lindenberg, et al.. (2020). Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib. The AAPS Journal. 22(4). 34 indexed citations

10.

Djebli, Nassim, Peter N. Morcos, Elena Guerini, et al.. (2020). Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing. Blood. 136(Supplement 1). 1–2. 14 indexed citations

11.

Morcos, Peter N., Elena Guerini, Joy Hsu, et al.. (2018). Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 82(1). 129–138. 24 indexed citations

12.

Hsu, Joy, Alice T. Shaw, Caicun Zhou, et al.. (2018). Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population.. Journal of Clinical Oncology. 36(15_suppl). e21133–e21133. 1 indexed citations

13.

Guerini, Elena, Simone Schadt, Gérard Greig, et al.. (2016). A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [¹⁴C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [¹³C₆]-labeled basimglurant in humans. Xenobiotica. 47(2). 144–153. 15 indexed citations

14.

Hsu, Joy, Volkmar Henschel, Katrijn Bogman, et al.. (2016). Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population.. Journal of Clinical Oncology. 34(15_suppl). e20598–e20598. 15 indexed citations

15.

Morcos, Peter N., Yumi Cleary, Elena Guerini, et al.. (2016). Clinical Drug–Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib. Clinical Pharmacology in Drug Development. 6(3). 280–291. 38 indexed citations

16.

Morcos, Peter N., Neil Parrott, Ludger Banken, et al.. (2016). Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects. Clinical Pharmacology in Drug Development. 6(3). 266–279. 9 indexed citations

17.

Fowler, Stephen, et al.. (2016). Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non–Michaelis-Menten P450 Kinetics on Fraction Metabolized. Journal of Pharmacology and Experimental Therapeutics. 360(1). 164–173. 5 indexed citations

18.

Parrott, Neil, et al.. (2014). Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin. The AAPS Journal. 16(5). 1077–1084. 26 indexed citations

19.

Moyle, Graeme, Marta Boffito, Chris Higgs, et al.. (2009). Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected Subjects. Antimicrobial Agents and Chemotherapy. 53(4). 1532–1538. 43 indexed citations

20.

Gaspari, Flavio, Norberto Perico, Piero Ruggenenti, et al.. (1995). Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate.. Journal of the American Society of Nephrology. 6(2). 257–263. 284 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact